Nordea Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.21M | Buy |
60,176
+22,509
| +60% | +$826K | ﹤0.01% | 714 |
|
|
2025
Q1 | $1.37M | Sell |
37,667
-2,006
| -5% | -$72.9K | ﹤0.01% | 760 |
|
|
2024
Q4 | $1.66M | Buy |
39,673
+3,246
| +9% | +$136K | ﹤0.01% | 714 |
|
|
2024
Q3 | $2.03M | Sell |
36,427
-1,386
| -4% | -$77.2K | ﹤0.01% | 687 |
|
|
2024
Q2 | $1.55M | Sell |
37,813
-7,230
| -16% | -$297K | ﹤0.01% | 737 |
|
|
2024
Q1 | $2.11M | Sell |
45,043
-422
| -0.9% | -$19.8K | ﹤0.01% | 702 |
|
|
2023
Q4 | $2.17M | Sell |
45,465
-921
| -2% | -$44K | ﹤0.01% | 691 |
|
|
2023
Q3 | $1.67M | Buy |
46,386
+49
| +0.1% | +$1.77K | ﹤0.01% | 726 |
|
|
2023
Q2 | $2.19M | Buy |
46,337
+27,569
| +147% | +$1.31M | ﹤0.01% | 679 |
|
|
2023
Q1 | $734K | Sell |
18,768
-754
| -4% | -$29.5K | ﹤0.01% | 845 |
|
|
2022
Q4 | $894K | Buy |
19,522
+537
| +3% | +$24.6K | ﹤0.01% | 792 |
|
|
2022
Q3 | $810K | Sell |
18,985
-1,232
| -6% | -$52.6K | ﹤0.01% | 811 |
|
|
2022
Q2 | $1.2M | Buy |
20,217
+11,066
| +121% | +$655K | ﹤0.01% | 758 |
|
|
2022
Q1 | $660K | Buy |
9,151
+1,459
| +19% | +$105K | ﹤0.01% | 864 |
|
|
2021
Q4 | $656K | Hold |
7,692
| – | – | ﹤0.01% | 881 |
|
|
2021
Q3 | $674K | Hold |
7,692
| – | – | ﹤0.01% | 883 |
|
|
2021
Q2 | $733K | Buy |
7,692
+728
| +10% | +$69.4K | ﹤0.01% | 858 |
|
|
2021
Q1 | $800K | Buy |
+6,964
| New | +$800K | ﹤0.01% | 809 |
|